ScreenerHero

INAB IN8bio, Inc.

NAS · US · Healthcare · Biotechnology · in8bio.com
1.400USD+0.72%Mkt Cap: 13.80M $P/E: —

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap13.80M USD
Enterprise Value-2.08M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.44M USD
Revenue/Share—
Last Price1.400 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.46
PEG—
EV/EBITDA0.12
EV/Revenue—
P/S—
P/B0.75
EPS (TTM)-1.62
EPS (Forward)-0.95
52W Range
0.880028% of range2.730
52W High2.730 USD
52W Low0.8800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-70.54%
ROA-60.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.71M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-57.35%
Net Debt-15.78M USD
Net Debt/EBITDA0.89
Balance Sheet
Debt/Equity0.10
Current Ratio8.21
Quick Ratio7.97
Book Value/Sh1.86 USD
Cash/Share1.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 6, 2025
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)+400.0%
Target Range5.000 USD – 10.00 USD
5.000+400.0% to mean10.00
# Analysts3
Ownership
Shares Out.9.86M
Float7.18M
Insiders7.58%
Institutions38.45%
Short Interest
Short Ratio1.5d
Short % Float0.72%
Short % Out.0.64%
Shares Short63.11K
Short (prev mo.)139.90K
Technical
SMA 501.127 (+24.3%)
SMA 2001.543 (-9.3%)
Beta0.30
S&P 52W Chg16.45%
Avg Vol (30d)44.70K
Avg Vol (10d)70.37K
Technical Indicators
RSI (14)65.5
MACD0.0724
MACD Signal0.0442
MACD Hist.+0.0282
BB Upper1.482 USD
BB Middle1.210 USD
BB Lower0.9370 USD
BB Width45.09%
ATR (14)0.0835 USD
Vol Ratio (20d)0.43x